RWA Civil Services
Current Affairs - Daily 17 November 2026

WHO Issues First Guidelines for Type 1 Diabetes in Adults: Focus on Insulin Access and Effective Treatment

WHO Issues First-Ever Guidelines for Type 1 Diabetes in Adults: Emphasis on Insulin Availability and Effective Treatment

Why in News?

On November 14, 2026, on the occasion of World Diabetes Day, the World Health Organization (WHO) released its first-ever dedicated guidelines for the diagnosis and management of Type 1 diabetes in adults.

The objective is to ensure the availability of affordable insulin, regular blood glucose monitoring, and quality treatment. These guidelines can also be implemented in resource-limited settings and during emergency and humanitarian crises.

 

What is Type 1 Diabetes?

Type 1 diabetes is an autoimmune disease in which the body's immune system destroys the insulin-producing beta cells of the pancreas, leading to a severe deficiency of insulin in the body.

  • This disease can develop in both children and adults.
  • Regular insulin treatment is essential for patients to survive.
  • Major symptoms include excessive thirst, frequent urination, weight loss, and fatigue.
  • Unlike Type 2 diabetes, Type 1 diabetes is primarily related to an autoimmune process.

Key Recommendations of WHO's New Guidelines

  • Insulin Treatment: Recommends multiple daily insulin injections, adjusting doses according to blood sugar levels.
  • Human Insulin: Human insulin has been considered an effective and suitable option due to its relatively lower cost. Insulin analogues can also be used as needed.
  • Glucose Monitoring: Use of regular blood glucose testing, finger-prick tests, and Continuous Glucose Monitoring (CGM).
  • HbA1c Testing: Assessment of the average blood sugar level over the past two to three months.
  • Resource-Limited Settings: Urine glucose testing may be considered when blood glucose testing is unavailable; however, it is not a complete substitute for blood glucose testing.

Global Situation and Important Statistics

  • According to WHO, approximately 9.5 million people worldwide were affected by Type 1 diabetes in 2025, with over half a million new cases reported that same year.
  • In 2022, approximately 830 million people worldwide were affected by all forms of diabetes.
  • Uncontrolled diabetes can lead to severe complications such as blindness, kidney failure, heart attacks, strokes, and lower-limb amputations.

Global Health Goals and Significance for India

  • WHO launched the Global Diabetes Compact in 2021.
  • A major global target is to ensure universal access to affordable insulin and self-monitoring of blood glucose for all individuals affected by Type 1 diabetes by 2030.
  • In India, the significance of these guidelines is particularly linked to rural health services, insulin availability, timely diagnosis, and continuity of care.

 

Conclusion

WHO's new guidelines are a significant step toward making Type 1 diabetes management more accessible, affordable, and patient-centered. Their success will depend on affordable insulin, regular monitoring, and robust primary healthcare services.

 

Multiple-Choice Question

Question: With reference to Type 1 diabetes and WHO's 2026 guidelines, consider the following statements:

  1. Type 1 diabetes is an autoimmune disease in which the insulin-producing beta cells of the pancreas are destroyed.
  2. WHO has recommended the use of insulin analogues exclusively for the treatment of Type 1 diabetes.
  3. The HbA1c test indicates the average blood sugar level over the past two to three months.
  4. WHO aims to ensure affordable insulin and self-monitoring of blood glucose for all individuals affected by Type 1 diabetes by 2030.

Which of the statements given above are correct?

(A) 1, 2 and 3 only

(B) 1, 3 and 4 only

(C) 2, 3 and 4 only

(D) 1, 2, 3 and 4

 

Answer: (B) 

 

Explanation: Statements 1, 3 and 4 are correct. Type 1 diabetes is an autoimmune disease, and HbA1c is an indicator of long-term blood sugar control. WHO has set a target for universal access to affordable insulin and self-monitoring of blood glucose by 2030. Statement 2 is incorrect because WHO has accepted the use of both human insulin and insulin analogues, prioritizing human insulin due to its lower cost.